FDA Publishes New Web Page on Impact of SARS-CoV-2 Viral Mutations on COVID-19 Molecular Tests and Upcoming CLIAC Meeting, April 14–15, 2021

COLA is engaged with the CDC’s Laboratory Outreach Communication System (LOCS) in the Division of Laboratory Systems (DLS) to transmit their public health messages to our laboratories and affiliates. Below are links to the most recent information about a new FDA Web Page on the impact of SARS-CoV-2 viral mutations on COVID-19 molecular tests and the upcoming Clinical Laboratory Improvement Advisory Committee (CLIAC) meeting, April 14–15, 2021.

FDA Publishes New Web Page on Impact of SARS-CoV-2 Viral Mutations on COVID-19 Molecular Tests

On March 30, 2021, the U.S. Food and Drug Administration (FDA) posted a new Web page for clinical laboratory staff and health care providers about the impact of viral mutations on COVID-19 molecular tests. The FDA will update this page as significant new information becomes available.

Upcoming CLIAC Meeting, April 14-15, 2021

General information and meeting topics are published at least 15 calendar days in advance in the Federal Register, with detailed agendas posted prior to the meeting. Meetings are open to the public and are also webcast.

Please visit this page prior to and during the meeting to access information as it becomes available, such as updated agendas, presentations, and handouts. Public comments can also be submitted in advance of the meeting for consideration by the Committee.